+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Osteoporosis Drugs Market - By Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Receptor Modulator, RANK Ligand Inhibitors, Biosimilars, and Others), By Regions (North America, Europe, Asia Pacific, and Rest of the World) - Global Forecast up to 2025

  • PDF Icon


  • 70 Pages
  • September 2019
  • Region: Global
  • IHR Insights
  • ID: 4857727
10% Free customization
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

This market research report includes a detailed segmentation of the global osteoporosis drugs market – by drug class (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Receptor Modulator, RANK Ligand Inhibitors, Biosimilars, and Others), and by Regions (North America, Europe, Asia Pacific, and Rest of the World).

Overview of the Global Osteoporosis Drugs Market Research:
The author's market research report predicts that the global osteoporosis drugs market will grow at a CAGR of 4.3% during the forecast period. Osteoporosis or porous bone or thinning bones is a disease associated by low bone mass and bone tissue structural deterioration, resulting in bone fragility and enhanced risk of fractures of the spine, hip and wrist. It mainly effects elderly population, especially women who have already experienced menopause.

Upsurge in the prevalence of osteoporosis in postmenopausal women, increase in aging population, and increasing awareness among public about osteoporosis care are some of the important factors driving the market growth. Aging population is major risk factor for the development of osteoporosis, nearly 9.9 million people live with osteoporosis in US and an additional 43.1 million have low bone mineral density (BMD). However, expiration of the patents and side-effects associated with the drugs such as nausea, difficulty in swallowing, heartburn, and gastric ulcer are some of the factors that may prove detrimental for the market. Growing investment in R&D for drug discovery and development and rising healthcare expenditure is anticipated to enhance the revenue of osteoporosis drugs market in next five years.

International Osteoporosis Foundation estimates that around 200 million individuals globally suffer from osteoporosis disease. Currently, it is estimated that over 200 million people worldwide suffer from this disease. Nearly 30% of all postmenopausal women have osteoporosis in the US and in Europe. According to National Institute of Health, about 53 million individuals in US either suffer from osteoporosis or at an increased risk due to low bone mass. The increasing patient base for osteoporosis diseases ensures constant growth of the market during the forecast period 2019 to 2025.

The industry generates majority of the revenue by the key players operating in this market few of them include Amgen, Inc., Eli Lilly & Company Ltd., Novartis AG, Pfizer Inc., Radius Health, Inc., and Merck & Co.

According to the author analysis, North America accounted for the largest share of the global osteoporosis drugs market in 2018 and will retain a high position during the forecast period. North America is followed by Europe with a share of more than 20% of the global market in 2018.

By Drug Class:
  • Bisphosphonates
  • Parathyroid Hormone Therapy
  • Selective Estrogen Receptor Modulator
  • RANK Ligand Inhibitors
  • Biosimilars
  • Others

In 2018, the bisphosphonates segment accounted for the largest share and is expected to grow at a low-single-digit CAGR by 2025. The biosimilars is expected to grow at a high CAGR during the forecast period 2019–2025. The patent of bestselling osteoporosis drugs is going to expire, which is paving way for the emergence of biosimilars. For instance, the patent of Amgen’s Prolia (Denosumab) will expire in the US in 2025 and in Europe in 2022. Currently there are five drug companies conducting ongoing clinical development of Denosumab biosimilar. Intas pharmaceuticals and AryoGen Pharmed are in advanced phase III clinical trial, whereas other two companies are in preclinical and pipeline phase.

By Regions:
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on geography, North America dominated the market in 2018 with a market share of over 40% and is expected to maintain this position throughout the forecast period. The presence of established medical and healthcare infrastructure, increasing patient base for osteoporosis, and existence of reputed players extensively involved in the commercialization of branded therapeutics make North America a dominant shareholder in the global osteoporosis drugs market. Asia Pacific is projected to grow at high CAGR during the forecast period 2019–2025.

Global Osteoporosis Drugs Market Research Competitive Analysis: The market is growing at a steady rate with a CAGR of 4.3% during the forecast period 2019–2025. There is an increase in new approvals, collaboration, and development of new osteoporosis drugs due to the increase in its incidence worldwide. For instance, FDA approved Evenity (romosozumab) to treat osteoporosis in postmenopausal women in April 2019 to those who have failed or intolerant to other osteoporosis therapies. South Korean based Yuyu Pharmaceutical launched Bazestar for the treatment of osteoporosis in late 2018. This drug is a selective estrogen receptor modulator used for treating and preventing osteoporosis in postmenopausal women.

In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new drugs to obtain a high share in the market. Sandoz announced start of clinical study for its proposed biosimilar denosumab for osteoporosis in July 2019. Iran based AryoGen Pharmed is conducting phase III trial for biosimilar Prolia and the trial is expected to be completed by the end of this year.

Key Vendors:
  • Amgen, Inc.
  • Novartis AG
  • Eli Lilly & Company Ltd.
  • Pfizer, Inc.
  • Radius Health, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • GlaxoSmithKline plc
  • Merck & Co.
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S

Key Competitive Facts:
  • Lasofoxifene (a new selective estrogen receptor modulator [SERM] or estrogen agonist-antagonist [EAA] with partial agonist activity at both estrogen receptors ERα and ERβ); abaloparatide (a parathyroid hormone [PTH]-related protein analog); balicatib (inhibitors of the resorptive enzyme cathepsin K) are some of the molecules currently undergoing clinical trial for Food and Drug Administration approval.
  • In March 2019, Pfenex announced an agreement with Alvogen to develop and commercialize PF708, a follow-on teriparatide product referencing Forteo to treat osteoporosis in the EU, some countries in North Africa, Middle East and other territories.

The report provides complete details about the sub-segment of the global osteoporosis drugs market. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the medical devices segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals and to analyze before investing or expanding the business in this market.

Key Takeaways:
  • Understanding the potential market opportunity with precise market size and forecast data.
  • Detailed market analysis focusing on the growth of osteoporosis drugs industry.
  • Factors influencing the growth of the osteoporosis drugs market.
  • In-depth competitive analysis of dominant and pure-play vendors.
  • Prediction analysis of the osteoporosis drugs industry in both developed and developing regions.
  • Key insights related to major segments of the osteoporosis drugs market.
  • Latest market trend analysis impacting the buying behavior of the consumers.

Table of Contents

1 Industry Outlook
1.1 Industry Overview
1.1.1 Global Driver for Pharmaceutical Demand
1.1.2 R&D Pipeline in Pharmaceutical Industry
1.1.3 Top Pharma Drugs by Sales (In $Million)
1.2 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition
3.2 Causes of Osteoporosis
3.3 Risk Factors for Osteoporosis
3.4 Symptoms of Osteoporosis
3.5 Segmented Addressable Market (SAM)
3.6 Trends of the Osteoporosis Drugs Market
3.7 Related Markets
3.7.1 Thrombosis Drugs
3.7.2 Immunotherapy Drugs
3.7.3 Oncology Drugs
4 Market Outlook
4.1 Market Segmentation
4.2 PEST Analysis
4.3 Porter 5 (Five) Forces
5 Market Characteristics
5.1 DRO –Market Dynamics
5.1.1 Drivers Increasing geriatric population and upsurge in the incidence of osteoporosis Growing awareness about osteoporotic care
5.1.2 Opportunities Rise in healthcare expenditure in developing countries Increased approval of new drugs and pipeline products
5.1.3 Restraints Expiration of patents and emergence of generics Side-effects associated with osteoporosis drugs
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Drug Class: Market Size and Analysis
6.1 Overview
6.2 Bisphosphonates
6.3 Parathyroid Hormone Therapy (PTH)
6.4 Selective Estrogen Receptor Modulator (SERM)
6.5 Rank Ligand Inhibitors
6.6 Biosimilars
6.7 Others
7 Regions: Market Size and Analysis
7.1 Overview
7.2 North America
7.3 Europe
7.4 APAC
7.4.1 Overview
7.5 Rest of the World
8 Competitive Landscape
8.1 Overview
9 Vendors Profile
9.1 Amgen, Inc.
9.2 Novartis AG
9.3 Eli Lilly & Company Ltd.
9.4 Pfizer Inc.
9.5 Radius Health, Inc.
10 Companies to Watch For
10.1 Teva Pharmaceutical Industries Ltd.
10.2 F. Hoffmann-La Roche Ltd.
10.3 GlaxoSmithKline plc
10.4 Novo Nordisk A/S
10.5 Merck & Co.
List of Tables
  • Global Osteoporosis Drugs Market Revenue, By Regions, 2018–2025 ($Million)
  • Other Vendors In The Osteoporosis Drugs Market
  • Business Summary: Amgen, Inc.
  • Business Summary: Novartis Ag
  • Business Summary: Eli Lilly & Company Ltd.
  • Business Summary: Pfizer Inc.
  • Business Summary: Radius Health, Inc.
  • Business Summary: Teva Pharmaceutical Industries Ltd.
  • Business Summary: F. Hoffmann-La Roche Ltd.
  • Business Summary: Glaxosmithkline Plc
  • Business Summary: Novo Nordisk A/S
  • Business Summary: Merck & Co.

List of Charts
  • Global Prescription Drug Sales, 2018–2025 ($Billion)
  • Global Over-The-Counter Drug Market Revenue, 2018–2025 ($Billion)
  • Global Pharma Sales, Biologics V/S Non-Biologics (%)
  • Global Pharmaceutical Sales By Region, 2018
  • Global Pharmaceutical R&D Spending (2010–2017)
  • Pharmaceutical Drugs By Sales, 2018 ($Billion)
  • Research Methodology of Global Osteoporosis Drugs Market
  • Global Osteoporosis Drugs Market Revenue, 2018–2025 ($Million)
  • Segmentation of Global Osteoporosis Drugs Market
  • Pest Analysis of Global Osteoporosis Drugs Market
  • Porter 5 Forces On Global Osteoporosis Drugs Market
  • Market Dynamics – DRO Analysis
  • DRO – Impact Analysis of Global Osteoporosis Drugs Market
  • Key Stakeholders
  • Global Osteoporosis Drugs Market, By Drug Class, 2018 V/S 2025 ($Million)
  • Global Bisphosphonates Market Revenue, 2018–2025 ($Million)
  • Global Parathyroid Hormone Therapy Market Revenue, 2018–2025($Million)
  • Global Selective Estrogen Receptor Modulator Market Revenue,2018–2025 ($Million)
  • Global Rank Ligand Inhibitors Market Revenue, 2018–2025 ($Million)
  • Global Biosimilars Market Revenue, 2018–2025 ($Million)
  • Global Others Market Revenue, 2018–2025 ($Million)
  • Global Osteoporosis Drugs Market By Geographical Segmentation, 2018 V/S 2025 (%)
  • Osteoporosis Drugs Market Revenue In North America, 2018–2025 ($Million)
  • Osteoporosis Drugs Market Revenue In Europe, 2018–2025 ($Million)
  • Osteoporosis Drugs Revenue In Asia Pacific, 2018–2025 ($Million)
  • Osteoporosis Drugs Market Revenue In Rest of The World, 2018–2025 ($Million)

Companies Mentioned

  • Amgen, Inc.
  • Novartis AG
  • Eli Lilly & Company Ltd.
  • Pfizer, Inc.
  • Radius Health, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • GlaxoSmithKline plc
  • Merck & Co.
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S